About Us
About Us
  • Board Of Directors
  • Collaborators
  • Staff Directory
  • Job Openings
Our Legacy
Our Legacy
  • Achievements
  • History
  • Irene Diamond
  • Photo Gallery
Current Research
Current Research
  • Our Scientists and Labs
    • Paul Bieniasz
    • Cecilia Cheng-Mayer
    • Theodora Hatziioannou
    • David D. Ho
    • Yaoxing Huang
    • Martin Markowitz
    • Moriya Tsuji
  • Core Facilities
    • Personnel
    • Flow Cytometry
    • Microscope Imaging Facility
Clinical Trials
Clinical Trials
  • HIV+
    • Newly Infected With HIV
    • Living With HIV
    • Physicians
    • FAQ's
  • HIV.
    • Healthy Volunteer
    • FAQ's
Focus On HIV
Focus On HIV
  • Facts About HIV and AIDS
  • HIV Biology
    • The HIV Virus Particle
    • The HIV Replication Cycle
Giving Center
Giving Center
  • Online Giving
  • Other Giving Opportunities
  • Financial Summary
News Center
News Center
  • ADARC In The News
  • Seminars
  • Newsletters and Brochures
  • For Journalists
China Aids Initiative
China Aids Initiative
Multimedia Library
Multimedia Library
Talks at ADARC
Talks at ADARC
ADARC Gala
ADARC Gala
  • Gala video
  • Gala photo
  • leadership committee
  • Online Giving
Register for Updates
Register for Updates
Clinical Trails

Healthy Volunteer


 

For Individuals Not Infected with HIV and Who Want to Help in the Fight Against HIV

Dr. David Ho and his associates conduct clinical trials in healthy, HIV-uninfected volunteers to develop potential vaccines to prevent HIV. We remain deeply committed to finding an HIV vaccine to help fight against the HIV/AIDS epidemic. We, along with others in the field, believe that a preventative HIV vaccine is vital to help decrease the infection rate of HIV/AIDS and help control the spread of HIV infection. Participation in HIV vaccine clinical trials provides opportunities for individuals to become involved in the fight against HIV/AIDS at a very personal level.


(MMA-0774)
Immune Activation HIV Negative IDU
The goal of this study is to learn how injection drug use may affect the immune system. We are enrolling HIV-negative injection drug users, HIV-negative people who do not use drugs and HIV-negative former injection drug users.

 

Study of the safety and tolerability of a long acting integrase inhibitor (GSK 744 LA) as PrEP)
This research study will test the safety and tolerability of an HIV drug that involves six shots over 9 months.